Biotech startup Cradle raises $24 million Series A to accelerate AI technology

The round was led by Index Ventures with participation from Kindred Capital and takes the total raised by the company to date to $33 million.

The company will use this funding to accelerate its growth, expand its machine learning and biotech team and continue to invest in its product development and sales capabilities.

Since exiting stealth in 2022, Cradle has onboarded nine industry partners including Johnson & Johnson Innovation, Novozymes, and Twist Bioscience.

The company’s platform applies generative AI and machine learning to the process of protein design to accelerate biotech research and development.

It is now working on more than 12 research and development projects focused on engineering a wide range of protein modalities including enzymes, vaccines, peptides and antibodies across a broad spectrum of protein properties.

Stef van Grieken, CEO and co-founder of Cradle, said: “Biological products are one of the biggest tools we can deploy to improve health outcomes and reduce the environmental impact of human consumption. By using generative AI and machine learning to help biologists design and optimise proteins faster and more efficiently, we can help research and development teams innovate faster, spend less and ultimately be more successful in developing new products.

“In the last year we’ve been focused on demonstrating that our technology can deliver meaningful results and initiating partnerships with a number of true industry leaders. We’re thrilled with the progress to date and are excited to have closed our Series A, which gives us everything we need to build on this momentum, accelerate our growth and onboard more customers to our platform.”

Leave a Reply

Your email address will not be published. Required fields are marked *